Ping-I Hsu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ping-I Hsu

Showing results (181-190 of 205) with videos related to

Pageof 21

Sort By:

Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 27, 2021

Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trialMeng-Shu Hsieh, Fu-Chen Kuo, Meng-Chieh Wu, et al.

Biomed Research International|June 20, 2015

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori InfectionGuang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, et al.

Helicobacter|August 14, 2021

Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infectionPing-I Hsu, Feng-Woei Tsay, John Y Kao, et al.

Helicobacter|January 10, 2017

Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scaleBor-Shyang Sheu, Ming-Shiang Wu, Cheng-Tang Chiu, et al.

Helicobacter|September 26, 2022

REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020Yoen-Young Chuah, Deng-Chyang Wu, Seng-Kee Chuah, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014

Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitisPing-I Hsu, Ching-Liang Lu, Deng-Chyang Wu, et al.

Helicobacter|August 31, 2018

The implementation of the consensus on the management of Helicobacter pylori and barriers to consensusHsiu-Chi Cheng, Jyh-Ming Liou, Jiing-Chyuan Luo, et al.

Journal of Neurogastroenterology and Motility|March 3, 2016

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific RegionKhean Lee Goh, Myung Gyu Choi, Ping I Hsu, et al.

Gastroenterology Research and Practice|August 14, 2012

7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in TaiwanSung-Shuo Kao, Wen-Chi Chen, Ping-I Hsu, et al.

Hepatology (Baltimore, Md.)|June 5, 2015

Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic areaPing-I Hsu, Kwok-Hung Lai, Jin-Shiung Cheng, et al.

Pageof 21

Search research articles

Showing results (181-190 of 205) with videos related to

Sort By:

Pageof 21

Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 27, 2021

Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trialMeng-Shu Hsieh, Fu-Chen Kuo, Meng-Chieh Wu, et al.

Biomed Research International|June 20, 2015

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori InfectionGuang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, et al.

Helicobacter|August 14, 2021

Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infectionPing-I Hsu, Feng-Woei Tsay, John Y Kao, et al.

Helicobacter|January 10, 2017

Helicobacter|September 26, 2022

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014

Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitisPing-I Hsu, Ching-Liang Lu, Deng-Chyang Wu, et al.

Helicobacter|August 31, 2018

The implementation of the consensus on the management of Helicobacter pylori and barriers to consensusHsiu-Chi Cheng, Jyh-Ming Liou, Jiing-Chyuan Luo, et al.

Journal of Neurogastroenterology and Motility|March 3, 2016

Gastroenterology Research and Practice|August 14, 2012

7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in TaiwanSung-Shuo Kao, Wen-Chi Chen, Ping-I Hsu, et al.

Hepatology (Baltimore, Md.)|June 5, 2015

Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic areaPing-I Hsu, Kwok-Hung Lai, Jin-Shiung Cheng, et al.

Pageof 21